Bulletin
Investor Alert

New York Markets Close in:

Dicerna Pharmaceuticals Inc.

NAS: DRNA

GO
/marketstate/country/us

Market open

 --Real time quotes

Sep 21, 2020, 1:07 p.m.

/zigman2/quotes/203776010/composite

$

18.89

Change

-0.96 -4.84%

Volume

Volume 196,412

Real time quotes

/zigman2/quotes/203776010/composite

Previous close

$ 19.85

$ 18.89

Change

-0.96 -4.84%

Day low

Day high

$18.68

$19.72

Open

52 week low

52 week high

$11.75

$27.68

Open

Company Description

Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of treatments for rare diseases, chronic liver diseases, cardiovascular disease, and viral liver infectious diseases. The firm uses its proprietary GalXC RNAi technology platform to build a p...

Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of treatments for rare diseases, chronic liver diseases, cardiovascular disease, and viral liver infectious diseases. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson and John J. Rossi in 2007 and is headquartered in Watertown, MA.

Valuation

Price to Sales Ratio

63.06

Price to Book Ratio

10.36

Price to Cash Flow Ratio

182.19

Enterprise Value to Sales

49.45

Total Debt to Enterprise Value

0.02

Efficiency

Revenue/Employee

127,829.00

Income Per Employee

-644,166.00

Receivables Turnover

0.16

Total Asset Turnover

0.05

Liquidity

Current Ratio

2.30

Quick Ratio

2.30

Cash Ratio

1.44

Profitability

Operating Margin

-536.25

Pretax Margin

-503.93

Net Margin

-503.93

Return on Assets

-23.94

Return on Equity

-68.27

Return on Total Capital

-68.11

Return on Invested Capital

-64.58

Capital Structure

Total Debt to Total Equity

15.44

Total Debt to Total Capital

13.37

Total Debt to Total Assets

3.93

Long-Term Debt to Equity

13.23

Long-Term Debt to Total Capital

11.46

Officers and Executives

Name Age Officer Since Title
Dr. Douglas M. Fambrough 50 2007 Director
Mr. James B. Weissman 57 2012 Chief Operating Officer & Executive Vice President
Mr. Douglas W. Pagán 47 2020 Chief Financial Officer
Mr. Shreeram Aradhye 57 2020 Chief Medical Officer
Dr. Bob D. Brown 54 2008 Chief Scientific Officer

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
09/14/2020 Bob D. Brown
See Remarks
267   Derivative/Non-derivative trans. at $3.42 per share. 913
09/01/2020 Douglas M. Fambrough
President and CEO; Director
10,000   Acquisition at $18.06 per share. 180,600
08/03/2020 James B. Weissman
EVP & Chief Operating Officer
1,432   Disposition at $22.8 per share. 32,649
08/03/2020 James B. Weissman
EVP & Chief Operating Officer
2,928   Disposition at $22.31 per share. 65,323
08/03/2020 Bob D. Brown
See Remarks
2,521   Disposition at $22.8 per share. 57,478
08/03/2020 Bob D. Brown
See Remarks
5,664   Disposition at $22.34 per share. 126,533
08/03/2020 James B. Weissman
EVP & Chief Operating Officer
259   Derivative/Non-derivative trans. at $3.42 per share. 885
08/03/2020 James B. Weissman
EVP & Chief Operating Officer
4,101   Derivative/Non-derivative trans. at $2.97 per share. 12,179
08/03/2020 Bob D. Brown
See Remarks
8,185   Derivative/Non-derivative trans. at $3.42 per share. 27,992
07/01/2020 James B. Weissman
EVP & Chief Operating Officer
1,307   Disposition at $26.87 per share. 35,119
07/01/2020 James B. Weissman
EVP & Chief Operating Officer
3,053   Disposition at $26.39 per share. 80,568
07/01/2020 Bob D. Brown
See Remarks
2,371   Disposition at $26.85 per share. 63,661
07/01/2020 Bob D. Brown
See Remarks
5,814   Disposition at $26.36 per share. 153,257
07/01/2020 James B. Weissman
EVP & Chief Operating Officer
4,360   Derivative/Non-derivative trans. at $2.97 per share. 12,949
07/01/2020 Bob D. Brown
See Remarks
8,185   Derivative/Non-derivative trans. at $3.42 per share. 27,992
06/19/2020 Bob D. Brown
See Remarks
9,670   Disposition at $25 per share. 241,750
06/19/2020 Bob D. Brown
See Remarks
9,670   Derivative/Non-derivative trans. at $2.97 per share. 28,719
06/01/2020 James B. Weissman
EVP & Chief Operating Officer
4,360   Disposition at $21.06 per share. 91,821
06/01/2020 Bob D. Brown
See Remarks
8,185   Disposition at $21.01 per share. 171,966
06/01/2020 James B. Weissman
EVP & Chief Operating Officer
4,360   Derivative/Non-derivative trans. at $2.97 per share. 12,949
06/01/2020 Bob D. Brown
See Remarks
8,185   Derivative/Non-derivative trans. at $3.42 per share. 27,992
05/11/2020 Bob D. Brown
See Remarks
13,281   Disposition at $24 per share. 318,744
05/11/2020 Bob D. Brown
See Remarks
13,281   Derivative/Non-derivative trans. at $2.97 per share. 39,444
05/05/2020 Bob D. Brown
See Remarks
8,185   Disposition at $21 per share. 171,885
05/05/2020 Bob D. Brown
See Remarks
8,185   Derivative/Non-derivative trans. at $3.42 per share. 27,992
05/04/2020 James B. Weissman
EVP & Chief Operating Officer
4,360   Disposition at $20.2 per share. 88,072
05/04/2020 James B. Weissman
EVP & Chief Operating Officer
4,360   Derivative/Non-derivative trans. at $2.97 per share. 12,949
04/20/2020 John B. Green
Chief Financial Officer
25,624   Disposition at $22.95 per share. 588,070
04/20/2020 Bob D. Brown
See Remarks
13,281   Disposition at $23 per share. 305,463
04/20/2020 John B. Green
Chief Financial Officer
25,624   Derivative/Non-derivative trans. at $5.45 per share. 139,650
04/20/2020 Bob D. Brown
See Remarks
13,281   Derivative/Non-derivative trans. at $2.97 per share. 39,444
/news/latest/company/us/drna

MarketWatch News on DRNA

  1. Arrowhead Stock’s Surge Will Continue, Analyst Says

    10:53 a.m. Nov. 29, 2019

    - Barron's Online

  2. Viex Capital Takes a Dip in Immersion Corp.

    9:30 p.m. June 7, 2019

    - Barron's Online

  3. Dicerna Pharmaceuticals stock price target raised to $26 from $20 at SunTrust RH

    8:57 a.m. March 13, 2019

    - Tomi Kilgore

  4. Legion Partners Sees Untapped Value in OneSpan

    12:50 a.m. Nov. 10, 2018

    - Barron's Online

  5. Dicerna Pharmaceuticals stock price target raised to $21.00 from $13.50 at B. Riley FBR

    10:01 a.m. Nov. 6, 2018

    - Tomi Kilgore

  6. Dicerna Pharmaceuticals upgraded to buy from neutral at B. Riley FBR

    10:01 a.m. Nov. 6, 2018

    - Tomi Kilgore

  7. Alexion stock rises 3% on Q3 beats, upbeat 2018 guidance

    7:49 a.m. Oct. 24, 2018

    - Emma Court

  8. Elliott Associates Likes Solid Service of Travelport

    8:53 p.m. March 30, 2018

    - Barron's Online

  9. Big Biotech Buys: Vericel, Achillion, PTC, Dicerna

    1:33 p.m. March 1, 2018

    - Barron's Online

  10. Dicerna Pharmaceuticals started at buy with $13 stock price target at SunTrust RH

    8:37 a.m. Feb. 5, 2018

    - Tomi Kilgore

  11. Lowe’s Is Adding Three New Directors to Board

    12:15 a.m. Jan. 27, 2018

    - Barron's Online

  12. Bain Makes Bank in Two Rebounding Biotechs

    8:58 a.m. Dec. 21, 2017

    - Barron's Online

/news/nonmarketwatch/company/us/drna

Other News on DRNA

  1. Dicerna Pharmaceuticals (DRNA) Investor Presentation - Slideshow

    2:16 p.m. Sept. 17, 2020

    - Seeking Alpha

  2. Dicerna Pharmaceuticals (DRNA) Investor Presentation - Slideshow

    10:55 a.m. Sept. 11, 2020

    - Seeking Alpha

  3. 10-Q: DICERNA PHARMACEUTICALS INC

    7:13 a.m. Aug. 6, 2020

    - Edgar Online - (EDG = 10Q, 10K)

  4. Four biotech names heading for key Q3 catalysts

    11:58 p.m. July 1, 2020

    - Seeking Alpha

  5. 10-Q: DICERNA PHARMACEUTICALS INC

    5:02 p.m. May 7, 2020

    - Edgar Online - (EDG = 10Q, 10K)

  6. Diving Into Dicerna Pharmaceuticals

    1:29 p.m. April 14, 2020

    - Seeking Alpha

  7. Loading more headlines...

At a Glance

Dicerna Pharmaceuticals, Inc.

33 Hayden Avenue

Lexington, Massachusetts 02421

Phone

1 6176218097

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2020

Revenue

$23.90M

Net Income

$-120.46M

2019 Sales Growth

287.0%

Employees

187.00

/news/pressrelease/company/us/drna

Press Releases on DRNA

  1. Gene Silencing Market Size, Status and Forecast 2020-2026

    1:28 a.m. Sept. 17, 2020

    - Market Insight Reports

  2. Dicerna Appoints Ling Zeng as Chief Legal Officer and Secretary

    7:30 a.m. Sept. 16, 2020

    - BusinessWire - BZX

  3. Friday 9/4 Insider Buying Report: RGT, DRNA

    1:46 p.m. Sept. 4, 2020

    - MarketNewsVideo.com

  4. Gene Silencing Market Growth And Status Explored In A New Research By 2025

    4:22 a.m. Sept. 3, 2020

    - Market Insight Reports

  5. Dicerna to Participate in Upcoming September Investor Conferences

    4:05 p.m. Sept. 2, 2020

    - BusinessWire - BZX

  6. Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    4:30 p.m. Sept. 1, 2020

    - BusinessWire - BZX

  7. Loading more headlines...
Trending Tickers
  • /quotes/zigman/17636479/composite VUZI+15.60%
  • /quotes/zigman/237947/composite JCP-5.83%
  • /quotes/zigman/59392505/composite NUGT-2.93%
  • /quotes/zigman/59386294/composite JNUG-5.94%
  • /quotes/zigman/65801738/composite TLT+1.11%
X
Powered by StockTwits
Link to MarketWatch's Slice.